Oncocyte renames to Insight Molecular Diagnostics (iMDx), ticker changes to IMDX on June 18

Insight Molecular Diagnostics Inc.

Company changed name from Oncocyte Corp to Insight Molecular Diagnostics Inc. effective June 13, 2025.
Stock ticker changes from OCX to IMDX, effective before market open on June 18, 2025.
Principal executive office relocated from Irvine, CA to Nashville, TN; CLIA lab already in Nashville.
Product rebranding: VitaGraft Kidney (LDT) → GraftAssureCore, RUO kit → GraftAssureIQ, future IVD kit → GraftAssureDx.
CEO letter reports progress toward FDA submission of transplant rejection test kit; three top-10 US transplant centers engaged.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Insight Molecular Diagnostics Inc.: Amended Article I of Articles of Incorporation to change company name from Oncocyte Corporation to Insight Molecular Diagnostics Inc (effective 2025-06-13).

Change: charter amendment
Effective: 2025-06-13

Exact text from the filing

In connection with the Name Change, the Company filed a Certificate of Ownership with the Secretary of State of the State of California on June 13, 2025, to amend Article I of the Company’s Articles of Incorporation solely to reflect the Company’s new corporate name.

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Insight Molecular Diagnostics Inc.: Amended and restated bylaws (Third Amended and Restated Bylaws) solely to reflect the company name change (effective 2025-06-13).

Change: bylaw amendment
Effective: 2025-06-13

Exact text from the filing

Also on June 13, 2025, the Company amended and restated the Company’s Second Amended and Restated Bylaws (the “Third Amended and Restated Bylaws”) solely to reflect the Name Change.

View on SEC.gov

Browse all governance changes →

Insight Molecular Diagnostics Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-015338

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.